Literature DB >> 28680830

Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cells.

Alex J Gooding1, William P Schiemann1.   

Abstract

Entities:  

Keywords:  Breast Cancer Metastasis; Chemoresistance; Mesenchymal-epithelial transition; Metastasis; Protein Kinase A; Tumor-initiating cell

Year:  2016        PMID： 28680830      PMCID： PMC5495186          DOI： 10.21037/tcr.2016.08.09

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  53 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

Review 2.  Regulation of actin-based cell migration by cAMP/PKA.

Authors:  Alan K Howe
Journal:  Biochim Biophys Acta       Date:  2004-07-05

3.  Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells.

Authors:  Toni Celià-Terrassa; Oscar Meca-Cortés; Francesca Mateo; Alexia Martínez de Paz; Nuria Rubio; Anna Arnal-Estapé; Brian J Ell; Raquel Bermudo; Alba Díaz; Marta Guerra-Rebollo; Juan José Lozano; Conchi Estarás; Catalina Ulloa; Daniel Álvarez-Simón; Jordi Milà; Ramón Vilella; Rosanna Paciucci; Marian Martínez-Balbás; Antonio García de Herreros; Roger R Gomis; Yibin Kang; Jerónimo Blanco; Pedro L Fernández; Timothy M Thomson
Journal:  J Clin Invest       Date:  2012-04-16       Impact factor: 14.808

Review 4.  Framework models of tumor dormancy from patient-derived observations.

Authors:  Christoph A Klein
Journal:  Curr Opin Genet Dev       Date:  2010-12-08       Impact factor: 5.578

Review 5.  A historical overview of protein kinases and their targeted small molecule inhibitors.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2015-07-21       Impact factor: 7.658

6.  Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.

Authors:  De-Chen Lin; Liang Xu; Ling-Wen Ding; Arjun Sharma; Li-Zhen Liu; Henry Yang; Patrick Tan; Jay Vadgama; Beth Y Karlan; Jenny Lester; Nicole Urban; Michèl Schummer; Ngan Doan; Jonathan W Said; Hongmao Sun; Martin Walsh; Craig J Thomas; Paresma Patel; Dong Yin; Daniel Chan; H Phillip Koeffler
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-27       Impact factor: 11.205

7.  3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition.

Authors:  M Drees; R Zimmermann; G Eisenbrand
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

8.  Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia.

Authors:  Lingzhi Zhang; Fiona Murray; Anja Zahno; Joan R Kanter; Daisy Chou; Ryan Suda; Michael Fenlon; Laura Rassenti; Howard Cottam; Thomas J Kipps; Paul A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-25       Impact factor: 11.205

Review 9.  Design of Next-Generation G Protein-Coupled Receptor Drugs: Linking Novel Pharmacology and In Vivo Animal Models.

Authors:  Sophie J Bradley; Andrew B Tobin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

10.  Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.

Authors:  Kari R Fischer; Anna Durrans; Sharrell Lee; Jianting Sheng; Fuhai Li; Stephen T C Wong; Hyejin Choi; Tina El Rayes; Seongho Ryu; Juliane Troeger; Robert F Schwabe; Linda T Vahdat; Nasser K Altorki; Vivek Mittal; Dingcheng Gao
Journal:  Nature       Date:  2015-11-11       Impact factor: 49.962
View more
  3 in total

Review 1.  Regulating cellular cyclic adenosine monophosphate: "Sources," "sinks," and now, "tunable valves".

Authors:  Michael Getz; Padmini Rangamani; Pradipta Ghosh
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2020-04-23

Review 2.  Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance.

Authors:  Alex J Gooding; William P Schiemann
Journal:  Mol Cancer Res       Date:  2020-06-05       Impact factor: 5.852

3.  Comparison of the uptake of untargeted and targeted immunostimulatory nanoparticles by immune cells in the microenvironment of metastatic breast cancer.

Authors:  Gil Covarrubias; Taylor J Moon; Georgia Loutrianakis; Haley M Sims; Mayura P Umapathy; Morgan E Lorkowski; Peter A Bielecki; Michelle L Wiese; Prabhani U Atukorale; Efstathios Karathanasis
Journal:  J Mater Chem B       Date:  2022-01-05       Impact factor: 6.331
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.